A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)

CompletedOBSERVATIONAL
Enrollment

1,758

Participants

Timeline

Start Date

November 29, 2017

Primary Completion Date

August 12, 2022

Study Completion Date

August 12, 2022

Conditions
Urothelial CarcinomaCarcinoma, Non-Small Cell LungSmall Cell Lung CarcinomaTriple Negative Breast CarcinomaHepatocellular Carcinoma
Interventions
DRUG

Atezolizumab

Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.

Trial Locations (56)

11765

Uijeongbu St. Mary's Hospital, Gyeonggi-do

13496

CHA Bundang Medical Center, Gyeonggi-do

14068

Hallym University Sacred Heart Hospital, Gyeonggi-do

14584

Soonchunhyang University Bucheon Hospital, Gyeonggi-do

14647

Bucheon St Mary's hospital, Gyeonggi-do

15355

Korea University Ansan Hospital, Gyeonggi-do

16247

St. Vincent's Hospital, Gyeonggi-do

24253

Hallym University Medical Center Chuncheon Sacred Heart Hospital, Gangwon-do

26426

Yonsei University Wonju Severance Christian Hospital, Gangwon-do

35365

Konyang University Hospital, Daejeon

41404

Kyungpook National University Medical Center, Daegu

41931

Keimyung University Dongsan Medical Center, Daegu

42472

Daegu Catholic University Medical Center, Daegu

42601

Keimyung University Dongsan Hospital; Pulmonology, Daegu

44033

Ulsan University Hosiptal, Ulsan

Ulsan University Hospital, Ulsan

46033

Dongnam Inst.of Radiological & Medical Sciences, Busan

47392

Inje University Busan Paik Hospital, Busan

48108

Inje university Haeundae Paik Hospital, Busan

49201

Dong-A University Hospital, Busan

49241

Pusan National University Hospital, Busan

49267

Kosin University Gospel Hospital, Busan

50612

Pusan National University Yangsan Hospital, Gyeongsangnam-do

54538

Wonkwang University School of Medicine & Hospital, Jeonlabuk-do

54907

Chonbuk National University Hospital, Jeollabuk-do

58128

Chonnam National University Hwasun Hospital, Jeollanam-do

602-715

Donga Uni Medical Center; Pulmonary, Busan

602-739

Pusan University Hospital, Busan

Unknown

Pusan University Hospital; Hemato-oncology, Busan

Gangneung Asan Hospital, Gangwon-do

Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si

Ewha Womans University Mokdong Hospital; Urology, Seoul

Korea Uni Anam Hospital; Internal Medicine, Seoul

SoonChunHyang University Hospital Seoul, Seoul

Pusan National University Yangsan Hospital; hemato-oncology, Yangsan

01812

Korea Cancer Center Hospital of Korea Institute of Radiological and Medical Sciences, Seoul

02841

Korea University Anam Hospital, Seoul

03181

Kangbuk Samsung Hospital, Seoul

03312

Eunpyeong St. Mary's Hoapital, Seoul

03722

Severance Hospital, Yonsei University Health System, Seoul

Severance Hospital, Yonsei University, Seoul

04401

Soonchunhyang University Hospital, Seoul

04763

Hanyang University Medical Center, Seoul

05278

Gangdong Kyung Hee University Hospital, Seoul

05368

VHS Medical Center, Seoul

05505

Asan Medical Center, Seoul

06273

Gangnam Severance Hospital, Seoul

06351

Samsung Medical Center, Seoul

06591

Seoul St Mary's Hospital, Seoul

06973

ChungAng University Hospital, Seoul

07061

Borame Medical Center, Seoul

07345

Yeouido St. Mary's Hospital, Seoul

08308

Korea University Guro Hospital, Seoul

120-752

Severance Hospital, Yonsei University Health System; Oncology, Seoul

135-710

Samsung Medical Centre; Division of Hematology/Oncology, Seoul

220-701

Yonsei University Wonju Severance Christian Hospital, Wŏnju

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT03232593 - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s) | Biotech Hunter | Biotech Hunter